← Back to scoreboard
HealthcareTMO
Thermo Fisher Scientific
Structurally advantaged — sells picks and shovels to every pharma company doing AI drug discovery. NVIDIA DGX Spark + NeMo + BioNeMo integration, OpenAI partnership, TetraScience collaboration.
AI Impact Score
8.0/10
↑↑ Very Positive
Scoring Breakdown
Sector Base
7
AI Revenue Exposure
8
Moat Durability
9
Disruption Risk (lower=better)
3
AI Adoption Maturity
9
Scenarios
Bull Case
Every pharma AI buildout increases instrument demand without TMO bearing clinical trial risk. 100K+ customers provide diversified revenue.
Bear Case
4-6% organic growth reflects post-COVID biotech hangover. AI-native lab automation startups represent long-run platform disruption risk.
Key Factors to Watch
- ●NVIDIA partnership (Jan 2026) positions TMO as AI-native lab infrastructure
- ●OpenAI + TetraScience create three-layer AI stack
- ●Every pharma AI buildout increases TMO demand without clinical trial risk
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-03-08 | 8.0 | Very Positive | Score 7.9→8.0 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.9 | Positive | Score 7.6->7.9 (md 8->9, aam 8->9). External research cross-ref: unmatched 5 AI partnerships (OpenAI, NVIDIA, BenchSci, TetraScience, Datavant), PPD+Clario clinical data moat, 100K+ employees on ChatGPT Enterprise |
| 2026-03-08 | 7.6 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-04-07
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.